COL19A1 is a predictive biomarker for the responsiveness of esophageal squamous cell carcinoma patients to immune checkpoint therapy.

Thoracic cancer（2023）

引用 0|浏览0

暂无评分

摘要

The findings of this study provide insight into the optimal design of individual treatments for ESCC patients.

查看译文

关键词

B cell infiltration,COL19A1,esophageal squamous cell carcinoma,neoadjuvant immunotherapy

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要